drugset / Trial / NCT05934942

A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood

NCT05934942

Phase 1 Terminated 29 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

This study aims to investigate the effect of multiple doses of BI 1358894 on pharmacokinetics of ethinylestradiol (EE) and drospirenone (DRSP) (Yasmin®)

Timeline

Start
2023-09-08
Primary completion
2024-02-08
Completion
2024-02-08

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1358894 Small molecule
Subject drospirenone Unknown
Subject ethinyl estradiol Small molecule

Indications

No indication recorded.